# US 10,500,188 B1 · Use of a polyenylpyrrole derivative in preparation of anti-oral cancer drugs

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,500,188 B1
- Document ID: US10500188B1
- Status: Granted
- Kind: B1
- Application number: 16/385,198
- Filed: 2019-04-16
- Granted: 2019-12-10
- Earliest claimed: 2019-01-28
- Assignees: Tzu Chi University
- Applicants: Tzu Chi University
- Inventors: Jeng-Woei Lee; Chia-Chen Lau; Kuo-Feng Hua; Yulin Lam
- Web page: https://patentgrep.com/patent/US10500188B1

## CPC

- A61K 31/4025: not condensed and containing further heterocyclic rings, e.g. cromakalim
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention discloses use of a polyenylpyrrole derivative in preparation of an anti-oral cancer drugs. The polyenylpyrrole derivative synthesized by polyvinylpyrrole, auxarconjugatin A and 12E-isorumbrin inhibits the cell proliferation, migration, tumor sphere formation abilities and xenograft tumorigenicity of oral cancer cells.

## Claims

### Claim 1

A polyenylpyrrole derivative used in preparation of anti-oral cancer drugs is used to inhibit oral cancer cells;
wherein the polyenylpyrrole derivative has a structural formula shown in the diagram below, including a hydrogen (H) atom and an ethyl (Et) group:

### Claim 2 (depends on 1)

The polyenylpyrrole derivative as claimed in claim 1, wherein the oral cancer cell is oral squamous cell carcinoma (OSCC) cell.

### Claim 3 (depends on 2)

The polyenylpyrrole derivative as claimed in claim 2, wherein the polyenylpyrrole derivative inhibits proliferation ability of the OSCC cell.

### Claim 4 (depends on 2)

The polyenylpyrrole derivative as claimed in claim 2, wherein the polyenylpyrrole derivative inhibits migration ability of the OSCC cell.

### Claim 5 (depends on 2)

The polyenylpyrrole derivative as claimed in claim 2, wherein the polyenylpyrrole derivative inhibits movement ability of the OSCC cell.

### Claim 6 (depends on 2)

The polyenylpyrrole derivative as claimed in claim 2, wherein the polyenylpyrrole derivative inhibits tumor sphere formation ability of the OSCC cell.

### Claim 7 (depends on 2)

The polyenylpyrrole derivative as claimed in claim 2, wherein the polyenylpyrrole derivative inhibits xenograft tumorigenicity of the OSCC cell.

### Claim 8 (depends on 2)

The polyenylpyrrole derivative as claimed in claim 2, wherein the polyenylpyrrole derivative enhances expression of prostate apoptosis response-4 (Par-4) in the OSCC cell.

### Claim 9 (depends on 2)

The polyenylpyrrole derivative as claimed in claim 2, wherein the polyenylpyrrole derivative inhibits expression of interleukin-17 receptor A (IL-17RA) in the OSCC cell.